Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Pzena Investment Management LLC

Pzena Investment Management LLC decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNGet Rating) by 29.0% during the 3rd quarter, HoldingsChannel reports. The fund owned 794 shares of the biopharmaceutical company’s stock after selling 325 shares during the quarter. Pzena Investment Management LLC’s holdings in Regeneron Pharmaceuticals were worth $547,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Ronald Blue Trust Inc. boosted its position in shares of Regeneron Pharmaceuticals by 157.9% during the 3rd quarter. Ronald Blue Trust Inc. now owns 49 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 30 shares during the last quarter. SeaCrest Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at about $40,000. Allworth Financial LP lifted its position in Regeneron Pharmaceuticals by 95.7% in the second quarter. Allworth Financial LP now owns 92 shares of the biopharmaceutical company’s stock valued at $54,000 after buying an additional 45 shares during the last quarter. Eagle Bay Advisors LLC acquired a new position in Regeneron Pharmaceuticals in the second quarter valued at about $60,000. Finally, Parkside Financial Bank & Trust lifted its position in Regeneron Pharmaceuticals by 36.4% in the third quarter. Parkside Financial Bank & Trust now owns 105 shares of the biopharmaceutical company’s stock valued at $73,000 after buying an additional 28 shares during the last quarter. Institutional investors and hedge funds own 84.25% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 0.3 %

Regeneron Pharmaceuticals stock opened at $727.47 on Wednesday. The company has a market capitalization of $79.22 billion, a P/E ratio of 15.34, a PEG ratio of 2.17 and a beta of 0.22. The company has a debt-to-equity ratio of 0.13, a quick ratio of 4.52 and a current ratio of 5.36. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $538.01 and a fifty-two week high of $779.00. The stock has a 50-day simple moving average of $732.22 and a 200-day simple moving average of $690.27.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Rating) last posted its quarterly earnings data on Thursday, November 3rd. The biopharmaceutical company reported $9.98 EPS for the quarter, beating analysts’ consensus estimates of $8.55 by $1.43. Regeneron Pharmaceuticals had a net margin of 39.17% and a return on equity of 31.16%. The company had revenue of $2.94 billion for the quarter, compared to analyst estimates of $2.79 billion. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 38.45 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Plew Daniel P. Van sold 11,972 shares of the business’s stock in a transaction that occurred on Wednesday, November 23rd. The stock was sold at an average price of $740.75, for a total value of $8,868,259.00. Following the transaction, the executive vice president now owns 30,578 shares of the company’s stock, valued at $22,650,653.50. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, EVP Plew Daniel P. Van sold 11,972 shares of the business’s stock in a transaction dated Wednesday, November 23rd. The shares were sold at an average price of $740.75, for a total transaction of $8,868,259.00. Following the transaction, the executive vice president now directly owns 30,578 shares in the company, valued at $22,650,653.50. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Marion Mccourt sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, November 4th. The shares were sold at an average price of $727.82, for a total value of $727,820.00. Following the completion of the sale, the executive vice president now directly owns 19,644 shares of the company’s stock, valued at $14,297,296.08. The disclosure for this sale can be found here. In the last ninety days, insiders sold 19,212 shares of company stock valued at $14,070,511. 8.99% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research firms have commented on REGN. Cowen upped their target price on shares of Regeneron Pharmaceuticals from $655.00 to $750.00 in a research report on Thursday, October 20th. Morgan Stanley upped their target price on shares of Regeneron Pharmaceuticals from $868.00 to $873.00 and gave the company an “overweight” rating in a research report on Tuesday. Cowen upped their target price on shares of Regeneron Pharmaceuticals from $655.00 to $750.00 and gave the company a “market perform” rating in a research report on Thursday, October 20th. EF Hutton Acquisition Co. I reaffirmed a “buy” rating and issued a $851.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, January 11th. Finally, StockNews.com started coverage on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 12th. They set a “hold” rating on the stock. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and fourteen have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $786.15.

Regeneron Pharmaceuticals Profile

(Get Rating)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Read More

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNGet Rating).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.